Early MRI predictors of disease-free survival in locally advanced rectal cancer from the GRECCAR 4 trial Journal Article


Authors: Nougaret, S.; Castan, F.; de Forges, H.; Vargas, H. A.; Gallix, B.; Gourgou, S.; Rouanet, P.; on behalf of the GRECCAR Study Group
Article Title: Early MRI predictors of disease-free survival in locally advanced rectal cancer from the GRECCAR 4 trial
Abstract: Background: Tailored neoadjuvant treatment of locally advanced rectal cancer (LARC) may improve outcomes. The aim of this study was to determine early MRI prognostic parameters with which to stratify neoadjuvant treatment in patients with LARC. Methods: All patients from a prospective, phase II, multicentre randomized study (GRECCAR4; NCT01333709) were included, and underwent rectal MRI before treatment, 4 weeks after induction chemotherapy and after completion of chemoradiotherapy (CRT). Tumour volumetry, MRI tumour regression grade (mrTRG), T and N categories, circumferential resection margin (CRM) status and extramural vascular invasion identified by MRI (mrEMVI) were evaluated. Results: A total of 133 randomized patients were analysed. Median follow-up was 41·4 (95 per cent c.i. 36·6 to 45·2) months. Thirty-one patients (23·3 per cent) developed tumour recurrence. In univariable analysis, mrEMVI at baseline was the only prognostic factor associated with poorer outcome (P = 0·015). After induction chemotherapy, a larger tumour volume on MRI (P = 0·019), tumour volume regression of 60 per cent or less (P = 0·002), involvement of the CRM (P = 0·037), mrEMVI (P = 0·026) and a poor mrTRG (P = 0·023) were associated with poor outcome. After completion of CRT, the absence of complete response on MRI (P = 0·004), mrEMVI (P = 0·038) and a poor mrTRG (P = 0·005) were associated with shorter disease-free survival. A final multivariable model including all significant variables (baseline, after induction, after CRT) revealed that Eastern Cooperative Oncology Group performance status (P = 0·011), sphincter involvement (P = 0·009), mrEMVI at baseline (P = 0·002) and early tumour volume regression of 60 per cent or less after induction (P = 0·007) were associated with relapse. Conclusion: Baseline and early post-treatment MRI parameters are associated with prognosis in LARC. Future preoperative treatment should stratify treatment according to baseline mrEMVI status and early tumour volume regression. © 2019 BJS Society Ltd Published by John Wiley & Sons Ltd
Keywords: adult; controlled study; unclassified drug; major clinical study; histopathology; fluorouracil; capecitabine; disease free survival; neoadjuvant therapy; nuclear magnetic resonance imaging; metastasis; multiple cycle treatment; phase 2 clinical trial; tumor volume; randomized controlled trial; continuous infusion; tumor regression; irinotecan; multicenter study; tumor recurrence; folinic acid; irradiation; phase 1 clinical trial; randomization; oxaliplatin; rectum cancer; diffusion weighted imaging; disease exacerbation; chemoradiotherapy; induction chemotherapy; time of death; total mesorectal excision; surgical margin; circumferential resection margin; echo planar imaging; locally advanced rectal cancer; human; male; female; priority journal; article; tumour response; extramural venous invasion; elvorin; lateral pelvic tilt; peritumoral drug administration; tumour replacement; tumour volume regression; tumour volumetry
Journal Title: British Journal of Surgery
Volume: 106
Issue: 11
ISSN: 0007-1323
Publisher: Oxford University Press  
Date Published: 2019-10-01
Start Page: 1530
End Page: 1541
Language: English
DOI: 10.1002/bjs.11233
PUBMED: 31436325
PROVIDER: scopus
PMCID: PMC8445107
DOI/URL:
Notes: Article -- Export Date: 1 November 2019 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors